Bumpus Namandje's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jun 22, 2026
- Accession no.
- 0001601830-26-000082
- Filed
- Jun 22, 2026
- Trade date
- Jun 17-18, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $12.6K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bumpus NamandjeCIK 0002060594 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Class A Common Stock | AGrant or awardAcquired | +88,424 | $0.00 | $0 | 131,595 | Direct | |
| Jun 18, 2026 | Class A Common Stock | SSaleDisposed | −3,963 | $3.18 | −$12,602.34 | 127,632 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.